Materials: The retrospective IRB approved study investigates the treatment group of 25 patients who underwent catheter based therapy consisting of single, or combination mechanical and chemical lytic therapy. The controls were patients with PE matched for similar severity of disease RV/LV ratio and other risk other factors. Controls were given medical management including systemic anticoagulation only. All available pre-and postprocedural cardiac imaging including CTA, and Echo were used to assess RV strain. Strain was measured using am established comparison of RV to LV diameters. Results: Over a one year, 25+patients at a single institution underwent catheter based therapy. Two devices had been used, either alone or in combination; Penumbra's Indigo, and BTG's Ekos were used. A roughly equal total dose of lytics (TPA) was given in both groups averaging 28 mg administered either single dose or 22hr infusion. Average preprocedure diagnosis was 1 day, and post procedure follow-up 1.8 days. RV/LV ratios between the two groups suggested a significant improvement right ventricular strain as measured by a change in RV/LV ratio. Conclusions: Catheter based therapy showed improvement in outcome measure vs medical management alone comparing right heart strain. A combination of catheter based tools including mechanical aspiration of clot, and directed lytics may be used in intermediate and high-risk PE patients safely. If widely available, catheter based therapy stands also to change the practices of Interventional physician's approach analogous to other cardiac emergencies such as STEMI creating the expectation expectation to provide emergent or semi-emergent responses.
Purpose: To determine the outcomes, safety profile, and efficacy of ultrasound-assisted catheter-directed thrombolysis for pulmonary embolism with right heart strain. Materials: The charts of 30 consecutive patients who underwent CDT as treatment for pulmonary embolism were reviewed. Risk factors for bleeding were noted. Indicators of right heart strain on computed tomography and echocardiogram, as well as degree of pulmonary vascular obstruction, were recorded before and after CDT. Thirty-day mortality and occurrence of bleeding events were recorded. Results: Right ventricular systolic pressure decreased from an average of 53.1 mm Hg to 38.5 mm Hg (p ¼ <0.001) and average Qanadli index of pulmonary vascular obstruction decreased from 49 to 34 (p ¼ <0.001) after CDT. The average ratio of RV/LV diameter decreased from 1.48 to 1.17 (p ¼ <0.001) The number of patients with RV hypokinesis decreased significantly (p ¼ 0.016) from 19 (95% of those with available data) to 12 (60%). The number of patients with RV dilation decreased significantly (p ¼ 0.031) from 19 (95% of those with available data) to 13 (65%).
Nine (30%) patients had three or more minor contraindications to thrombolysis and fourteen (47%) had had major surgery in the month prior to CDT. No patients experienced major or moderate bleeding attributed to CDT. Conclusions: In our experience CDT proved effective in the rapid alleviation of right heart strain with minimal bleeding risk. Right heart strain is associated with increased mortality and longterm morbidity in pulmonary embolism and CDT may allow for a safe means of improving outcomes in submassive pulmonary embolism. We found CDT to be a safe alternative to systemic thrombolysis in patients with risk factors for bleeding such as prior surgery.
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The thromboaspiration with INDIGO system reduces the time and dose of fibrinolysis and improves the results in massive pulmonary embolism in comparison with catheter fragmentation (previous cohort study) Purpose: Determine if thromboaspiration with indigo system improves short-and medium-term outcomes compared with interventional treatment of choice for pulmonary embolism (PE) (mechanical thrombolysis + catheter-directed thrombolytic therapy). Materials: From Apr-2016 to Aug-2017, 43 patients diagnosed massive PE and a comparative with previous study of 111 patients with massive PE. In the first cohort all patients were treated with thromboaspiration + catheter-directed thrombolytic therapy (TAs) and the other cohort were treated with conventionally according to our protocol: thrombolysis + catheter fragmentation (MFT). There were no significant differences in age, sex and the angiographic pulmonary index (Miller index). Pulmonary pressures after fibrinolysis and one month later were compared. The total dose and the total time of fibrinolysis were also compared in both groups. Results: Postoperative mean pulmonary arterial pressure (PAPm) was 34. Purpose: Emerging evidence suggests ultrasound-assisted catheter-directed thrombolysis (UACDT) decreases right ventricular dilation, reduces pulmonary hypertension, and minimizes risk of intracranial hemorrhage in patients with acute submassive pulmonary embolism (PE). It is important to identify clinical factors that may affect these patients' hospital stays to facilitate patient care. We aimed to evaluate factors associated with the length of intensive care unit (ICU) and hospital stays in acute submassive PE patients who underwent UACDT. Materials: Clinical data of patients who underwent UACDT (EkoSonic™ Endovascular System, Bothell, Washington) for submassive PE between 1/2016 and 7/2017 was reviewed. Tissueplasminogen activator was administered at 1 mg/h for 12 hours and titrated per Fibrinogen levels. Linear regression was used to evaluate the association with log-transformation of non-parametric length of stay data. Results: Among the 31 patients enrolled, 17 were male. The mean (±SD) age was 54 ± 17 years. The mean (±SD) Pulmonary Embolism Severity Index and RV/LV ratio were 92 ± 38 and 1.34 ± 0.36, respectively. The median troponin and BNP levels were 0.117 and 251, respectively. The median length of ICU and hospital stays were 45 hours and 5 days, respectively. There were no complications. After adjusting for all factors in the regression model, the RV/LV ratio was significantly associated with longer ICU (b-coefficient ¼ 0.87, 95%CI 0.29,1.45, p ¼ 0.005) and hospital stays (b-coefficient ¼ 1.27, 95%CI 0.52,2.01, p ¼ 0.002). Conclusions: UACDT is safe for submassive (intermediate-high risk) PE patients with the median length of ICU and hospital stays of 45 hours and 5 days, respectively. Increased RV/LV ratio is associated with longer ICU and hospital stays. Our data suggests that RV dilation is an important prognostic factor of these patients. 
